Get started
Author

Ineza O. Sharvashidze

Observed names: I. O. Sharvashidze, Шарвашидзе Инеза Отариевна
Observed institution: City Clinical Oncology Center
ORCID: 0009-0008-2518-3778
Observed ORCID: 0009-0008-2518-3778
OpenAlex ID: A5069917797
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study
2022 · Tatyana N. Sokolova, Tatyana I. Solov'eva, et al. · Journal of Modern Oncology · 3
PDF
Clinical and Morphological Features of ER-Positive HER2-Negative Breast Tumors with PIK3CA Mutations in Russian Patients
2025 · Tatyana N. Sokolova, Grigory A. Yanus, et al. · Cancers · 2
PDF
Next generation antibody-drug conjugates in the treatment of her2-positive metastatic breast cancer: literature review and clinical case demonstration.
2025 · M. I. Gluzma, I. O. Sharvashidze · Clinical Case in Oncology
PDF
Tolerability of dose-dense and standard regimens of neoadjuvant chemotherapy in estrogen receptor-positive/HER2-negative breast cancer: results of a prospective observational study
2025 · R. V. Orlova, A. A. Vakhitova, et al. · Podderživaûŝaâ terapiâ v onkologii.
PDF
Phase II study of lapatinib and tegafur combination efficacy for the treatment of HER2+ metastatic breast cancer.
2012 · Alexey Manikhas, Ineza O. Sharvashidze, et al. · Journal of Clinical Oncology
Works count: 6
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type